What is Biocartis Group N.V. (BIOGF)?

Biocartis Group N.V. (BIOGF) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of BIOGF?

The current price of BIOGF is $0.66. Prices are updated in real time on Stocks360.

What is BIOGF's price-to-earnings (PE) ratio?

BIOGF's trailing twelve-month PE ratio is -0.55, based on current price and earnings per share data available on Stocks360.

What is BIOGF's market capitalization?

BIOGF's market capitalization is $65,406,204.00, placing it in the small-cap tier.

Biocartis Group N.V. (BIOGF)

Stock analysis · OTC · Healthcare · Medical - Diagnostics & Research

$0.66

Market Cap

$65.41M

PE (TTM)

-0.55

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.39

Day Range

$0.66 – $0.66

52-wk Range

$0.66 – $0.66

Avg Volume

N/A

Volume

3.30K

Biocartis Group N.V. (BIOGF) is a publicly traded company in the Healthcare sector. Latest price: $0.66. Market cap $65.41M. Trailing PE -0.55. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Biocartis Group N.V.

Biocartis Group N.V. is a molecular diagnostics firm dedicated to advancing clinical practice through innovative diagnostic solutions. These offerings aim to benefit patients, clinicians, healthcare payers, and the wider healthcare industry, with a particular emphasis on the field of oncology. Central to their product portfolio is the proprietary Idylla platform, a real-time polymerase chain reaction (PCR) system. This cutting-edge technology delivers vital molecular information, which is instrumental in both selecting appropriate treatments and continuously monitoring their effectiveness. The company provides a diverse array of Idylla tests, including mutation analyses for oncology biomarkers such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Beyond cancer diagnostics, they also offer panels for infectious diseases, specifically Idylla SARS-CoV-2/Flu/RSV and standalone SARS-CoV-2 tests. Additionally, their SeptiCyte RAPID test offers quick assessment of host response. For research purposes, Biocartis supplies various assays for detecting mutations, including those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.55×
P/S (TTM)	1.02×
P/B	-1.18×
P/FCF (TTM)	-1.25×
EV / EBITDA	-3.54×
EV / Sales	2.71×
Earnings Yield	-183.32%
Free Cash Flow Yield	-80.16%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$155.81M
Revenue (TTM)	$57.48M
Net Income (TTM)	-$107.01M
Free Cash Flow (TTM)	-$35.65M
Net Debt	$97.43M
Working Capital	$27.48M
Gross Margin	48.16%
Operating Margin	-81.85%
Net Margin	-113.74%
Return on Equity	203.74%
Return on Invested Capital	-50.72%